Evidence map›Paper›PMID 40872325›Full record

ArticlePathogens (Basel, Switzerland)2025

Relationship Between Cell Surface Viral Glycoprotein Expression and Resistance of Parainfluenza Virus Persistently Infected Cells to Complement-Mediated Lysis.

Nasser N Yousef, Griffith D Parks

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nasser N YousefBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
Griffith D ParksBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.

Funding

Complement Resistance Acquired During Acute to Persistent Rubulavirus InfectionR21AI175591 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI PARKS, GRIFFITH D. · 2023 to 2024
$431k
NIAID NIH HHS R21 AI175591NIH HHS AI175591
6 · The paper itself

Abstract

Persistent RNA virus infections (PI) are often characterized by extended viral shedding and maintained cycles of inflammation. The innate immune Complement (C') pathways can recognize acute infected (AI) cells and result in their lysis, but the relative sensitivity of PI cells to C'-directed killing is incompletely understood. Here, we extended our previous studies on the interactions of C' with parainfluenza virus AI and PI A549 cells to two additional respiratory tract cell lines. AI Hep2 and H1975 cells infected with Parainfluenza virus 5 (PIV5) were found to be highly sensitive to C' lysis. By contrast, PIV5 PI cells were highly resistant to killing by C″. Surface deposition of membrane attack complex (MAC) and C3 was also greatly reduced on the surface of PI cells compared to AI cells. PI cells had lower levels of surface viral glycoprotein expression compared to AI cells. Treatment of AI cells with ribavirin (RBV) showed a dose-dependent decrease in both viral glycoprotein expression and sensitivity to C'-mediated lysis. When surface viral glycoprotein levels were reduced in AI cells to those in PI cells, AI cells became similarly resistant to C'. While sialic acid levels on PI cell surfaces matched that of naïve cells, enzymatic removal of this sialic acid did not increase sensitivity to C'-mediated lysis. Despite their varying profiles of C' activation and deposition, these studies indicate downregulation of viral gene expression as a common mechanism of C' resistance across various parainfluenza virus PI cell lines.

Indexed as

Complement System ProteinsParainfluenza Virus 5A549 CellsAntiviral AgentsCell LineHumansParamyxoviridae InfectionsRibavirinAntiviral AgentsComplement System ProteinsRibavirincomplementparamyxovirusespersistent infections

Identifiers

PMID40872325
PMCPMC12388906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.